Related to Chronix Opens South Dakota Sequencing Lab for Cancer and Rare Disease Services

• Antibody-Drug Conjugates to Fight Cancer
  While mAbs have been extremely successful, these empowered antibodies are touted as the next big blockbusters.
  
• Avastin: Time for a Predictive Test
  Roche’s strategy to expand the use of Avastin into the first-line and adjuvant settings is particularly dependent on identifying those most likely to see a benefit.
  
• Nanotechnology Enables Precise Cancer Targeting
  While first-generation nanodrugs reduced toxicity, next-gen treatments are being designed to increase efficacy.
  
• Human Genome Redux: Just a Numbers Game?
  Success of sequencing capabilities is dependent on tools to analyze the data.
  
• Changes Brewing at the FDA for Orphan Drugs
  Initiatives to de-risk drug development could include redesigning clinical trial requirements.
  
• What Comes After Dendreon’s Provenge?
  Success of prostate cancer vaccine has ushered in a wave of autologous vaccine development.
  
• Will a Nonautologous Cancer Vaccine Be the Next to Make It Through Approval?
  In the race to mimic Dendreon’s success with Provenge, off-the-shelf products make for attractive opportunities.
  
• Tales from the Biotech Crypt: Sam Waksal Is Back in Business
  Former ImClone CEO has started a new firm, made three acquisitions including Three Rivers, and begun licensing.
  
• Melanoma Cells: All Stem Cells in Disguise?
  Researchers believe that the cancer stem cell theory may not apply to all cancers.
  
• Getting Personal: Multigene Testing for Individual Cancer Evaluation
  Scientists find comfort in numbers, using molecular patterns as prognostic markers.
  
• 2010 in Review: Biotechnology Highlights
  Gene patenting and ESCs were back in the headlines along with breakthroughs in sequencing, syn bio, and other fields.
  
• Tumor Cells Back in Circulation for Monitoring Cancer
  With one test on the market, researchers are developing tools that leverage CTCs as biomarkers.
  
• What’s Wrong with Phase II Trials?
  A better early-phase clinical plan could address high attrition rates in Phase III.
  
• While Advocacy Abounds, Orphan Drug Development Success Remains Elusive
  Questions persist about whether legislature can translate ongoing research into medications.
  
• Biotechs Nail Down Sequence of Elusive E. coli
  A new hybrid strain is responsible for the European outbreak that’s been all over the news.
  
• Companies with Cancer Therapeutic Candidates Ramp Up Companion Diagnostic Efforts
  As regulatory framework gets fine-tuned, firms realize the importance of having a biomarker strategy.
  
• Does Clinical Success Mean Commercial Success for Cancer Vaccines?
  Getting insurers to pay for immunotherapies and keeping doctors more informed are key to market growth.
  
• Product and Service Firms Challenged by Uncertain NIH Funding, Polarization of Sequencing
  Analysts and vendors are preparing for low to no growth in 2012 and 2013.
  
• Exome Sequencing Finds Sweet Spot Between Whole-Genome and Targeted Sequencing
  Technique provides a cost-effective tool for dissecting diseases that have been intractable to conventional gene discovery.
  
• Vaccine Isotype Seems to Affect Clinical Outcome in Blood Cancer Trials
  New results presented at ASH will impact production of autologous immunotherapies.